Potentiation of the bleomycin, arabinofuranosylcytosine and adriamycin-caused inhibition of DNA synthesis in lymphocytes by bestatin in vitro.
Combinations of 1-beta-D-arabinofuranosylcytosine (araC), bleomycin (BLM) or adriamycin (ADM) with the dipeptide bestatin do not result in an enhanced in vitro cytotoxicity in the macrophage-free L5178y mouse lymphoma cell system. However, in macrophage-containing murine spleen lymphocytes bestatin causes a potentiating effect of the cytostatic drugs araC, BLM and ADM with respect to their potencies to inhibit DNA synthesis. In the presence of 1 microgram bestatin/ml, the ED50 concentrations causing a 50% reduction of [3H]dThd incorporation were significantly lowered; 4.3-fold in the studies with araC and BLM, and 1.8-fold in the experiments with ADM. Bestatin, given alone, displays a stimulating effect on [3H]dThd incorporation into macrophage-containing lymphocyte cultures within the concentration range 0.1-10 micrograms/ml. In contrast to the bestatin-stimulated lymphocytes, ConA-stimulated as well as LPS-stimulated lymphocytes do not show a higher sensitivity to the selected drugs inhibiting DNA synthesis. These data should encourage the practical use of bestatin in combination with araC, BLM or ADM in cancer treatment.